Going Public: Strengthening Germany as a financing location (in German)

Why do vaccine manufacturers like BioNTech or CureVac go public in the USA and not in Germany? The decisive factor for listing in the USA is the much more attractive capital market ecosystem with financially strong, specialised pension funds. In their article, Birgit Homburger and Dr. Norbert Kuhn therefore call on the next federal government to add a savings scheme with shares to old-age provision. This would also create pension funds with a strong capital base in this country. More money flows into the capital market with positive effects for the financing of young growth companies.

The article by Birgit Homburger and Norbert Kuhn was published by Going Public and is part of the Deutsches Aktieninstitut's series on the Bundestag elections.